23:22 , Oct 11, 2018 |  BC Week In Review  |  Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
20:10 , Oct 9, 2018 |  BC Extra  |  Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
00:03 , Dec 16, 2017 |  BC Extra  |  Company News

Management tracks: Chugai, bioMérieux

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said President and COO Tatsuro Kosaka will become president and CEO. He succeeds CEO Osamu Nagayama, who will remain chairman. Diagnostics company bioMérieux S.A. (Euronext:BIM) said Deputy CEO Alexandre Mérieux...
04:28 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Atlas Genetics completes venture financing

Molecular diagnostics company Atlas Genetics Ltd. (Trowbridge, U.K.) raised $35 million in a series D round on Jan. 23. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc, the Johnson...
00:37 , Jan 24, 2017 |  BC Extra  |  Financial News

Atlas Genetics raises $35M in series D

Molecular diagnostics company Atlas Genetics Ltd. (Trowbridge, U.K.) raised $35 million in a series D round. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc (LSE:CSRT), the Johnson & Johnson...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

Io Chlamydia trachomatis test regulatory update

Atlas Genetics received CE Mark approval for the io Chlamydia trachomatis test to detect chlamydia. The test is a point-of-care in vitro diagnostic for use on Atlas’ automated io system. Atlas Genetics Ltd. , Trowbridge,...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Atlas Genetics deal

Atlas and an undisclosed pharmaceutical company partnered to develop Atlas’ io point-of-care infectious disease diagnostic outside of infectious disease. Atlas did not provide details. Atlas Genetics Ltd. , Trowbridge, U.K.   Business: Diagnostic  ...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Financial News

Atlas Genetics completes venture financing

Atlas Genetics Ltd. , Trowbridge, U.K.   Business: Diagnostic   Date completed: 2015-01-29   Type: Venture financing   Raised: $20 million   Investors: RMI Partners; Novartis Venture Funds; Consort Medical plc ; Johnson & Johnson...
02:46 , Jan 30, 2015 |  BC Extra  |  Financial News

Atlas Genetics raises $20M in series C round

Diagnostics company Atlas Genetics Ltd. (Trowbridge, U.K.) raised $20 million in a series C round from new investor RMI Partners, a subsidiary of Rusnano, and existing investors Novartis Venture Funds; Consort Medical plc ; Johnson...